Skip to Content

FDA Approves 'Biosimilar' Drug Ogivri for Breast, Stomach Cancers

FRIDAY, Dec. 1, 2017 -- Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as the nation's first biosimilar drug to treat certain breast and stomach cancers, the agency said Friday in a news release.

The maker of a biosimilar, derived from a living organism, must demonstrate that the new product is "highly similar" to an already approved medication, and that it has no clinically significant difference in terms of its potency, safety and purity, the FDA said.

Ogivri is approved to treat breast or stomach cancers attributed to a problematic HER2+ gene. The FDA said its maker, Mylan, provided sufficient evidence that the drug is biosimilar to the Genentech drug Herceptin, which was approved by the agency in 1998.

"The FDA continues to grow the number of biosimilar approvals, helping to promote competition that can lower health care costs," said FDA Commissioner Dr. Scott Gottlieb. "This is especially important when it comes to a disease like cancer, that has a high cost burden for patients."

Expected side effects for Ogivri include headache, diarrhea, nausea, chills, fever, infection, congestive heart failure, insomnia, cough and rash, the FDA said.

Like Herceptin, Ogivri's label will include a boxed warning about an increased risk of heart disease, serious allergic-like reactions, lung damage and harm to a developing fetus, the agency said.

Mylan is based in Canonsburg, Penn.

© 2020 HealthDay. All rights reserved.

Posted: December 2017

Read this next

Many Male Breast Cancers Diagnosed Late, and Delays Can Be Lethal

THURSDAY, Oct. 15, 2020 -- Breast cancer in men is rare. But because it's not often suspected in men, diagnosis often comes only after a tumor has begun to spread throughout the...

Cancer Takes Heavy Toll on Women's Work and Finances: Study

MONDAY, Oct. 12, 2020 -- Young women with cancer are at a high risk for employment and financial consequences, a new study finds. "Our study addresses the burden of employment...

Radiation Plus Surgery May Be Best Against an Early Form of Breast Cancer

MONDAY, Oct. 5, 2020 -- Research following patients for nearly three decades finds that surgery plus radiation beats surgery alone for women with ductal carcinoma in situ (DCIS)...